SCHEDULE: Venrock Group Discloses 7.3% Stake in Savara Inc.

A group of Venrock entities and individuals has reported a 7.3% beneficial ownership stake in Savara Inc. as of September 30, 2025.

Summary

• A group of Reporting Persons, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Y. Koh, has filed an amendment to their Schedule 13G.
• The Reporting Persons collectively beneficially own 12,681,043 shares of Savara Inc. common stock.
• This ownership represents 7.3% of Savara Inc.'s total outstanding common stock.
• The percentage is calculated based on 172,836,922 shares of common stock outstanding as of August 13, 2025, as reported in Savara Inc.'s Quarterly Report on Form 10-Q.
• The ownership is distributed among VHCP III (2,783,186 shares), VHCP Co-Investment III (278,376 shares), and VHCP EG (9,619,481 shares).
• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of Savara Inc.

Sentiment

Score: 7

Explanation: The filing indicates a substantial and continued beneficial ownership by a group of Venrock Healthcare Capital Partners entities and individuals, which can be interpreted as a vote of confidence from a sophisticated investor in the healthcare sector.

Positives

• A significant institutional investor group, Venrock Healthcare Capital Partners, maintains a substantial 7.3% stake in Savara Inc., indicating continued confidence in the company's prospects.

Future Outlook

NA

Industry Context

The disclosure of a significant stake by a specialized healthcare capital firm like Venrock in Savara Inc. suggests continued investor interest in the biotechnology or pharmaceutical sector, particularly in companies like Savara that are likely involved in drug development or healthcare innovation. Such filings provide transparency into institutional positioning within the industry.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership by an institutional investor group, common across all industries.
• Venrock Healthcare Capital Partners is a known entity in the healthcare investment space, and their continued significant stake in Savara Inc. aligns with typical venture capital or private equity firm strategies of maintaining positions in portfolio companies.
• No specific comparable companies or projects are mentioned in the filing itself.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which could influence market perception and trading activity. It confirms a large block of shares is held by a long-term focused healthcare investor.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a transparency document, confirming that Venrock Healthcare Capital Partners and related entities continue to hold a substantial 7.3% stake in Savara Inc. While the presence of a sophisticated healthcare investor is generally a positive indicator of confidence, this filing does not introduce new operational or financial performance data that would fundamentally alter an investment thesis. Therefore, an investor would likely maintain their current position, acknowledging the institutional backing without immediate action based solely on this ownership update.

Keywords

Savara Inc., SVRA, Venrock Healthcare Capital Partners, institutional ownership, Schedule 13G, beneficial ownership, common stock, biotechnology investment, healthcare investment